Physician profile
Sahdev Saharan
NPI 1588875512
$23,837.42
in general payments reported to CMS, 2019-2025
35 companies · $5,098 in 2025
The $5,098 reported for 2025 was more than what 86% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,323 · 2020: $2,121 · 2021: $3,270 · 2022: $4,072 · 2023: $3,918 · 2024: $4,035 · 2025: $5,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,803.07 |
| Education | $248.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,613.90 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Janssen Biotech, INC. | $2,887.78 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $2,334.08 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $1,855.19 | 2019-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $1,844.67 | 2019-2025 | Benlysta |
| Horizon Therapeutics Plc | $1,436.56 | 2020-2023 | Krystexxa, Tepezza |
| Novartis Pharmaceuticals Corporation | $1,290.33 | 2019-2025 | |
| Pfizer INC. | $1,081.60 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,067.24 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $831.53 | 2020-2025 | Orencia, Opdualag |
| Aurinia Pharma U.S., INC. | $668.07 | 2021-2024 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $612.60 | 2019-2025 | Ofev, Cyltezo |
| Genentech USA, INC. | $600.17 | 2020-2025 | Actemra, Gazyva, Rituxan |
| Fresenius Kabi USA, LLC | $434.37 | 2023-2025 | Idacio, Adalimumab-Aacf |
| Ani Pharmaceuticals, INC. | $369.28 | 2022-2025 | Purified Cortrophin Gel |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $335.43 | 2020-2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $327.53 | 2020-2025 | Strensiq, Ultomiris |
| Lilly USA, LLC | $284.23 | 2019-2025 | Taltz |
| Genzyme Corporation | $186.21 | 2020-2025 | |
| Janssen Scientific Affairs, LLC | $161.23 | 2019-2022 | |
| Sandoz INC. | $79.87 | 2023-2024 | Hyrimoz |
| Organon LLC | $60.21 | 2023-2025 | Hadlima, Renflexis |
| Scilex Pharmaceuticals INC. | $54.53 | 2024-2025 | |
| Celltrion USA INC. | $50.46 | 2023 | Yuflyma |
| Tersera Therapeutics LLC | $47.78 | 2025 | Quzyttir |
| Actelion Pharmaceuticals US, INC. | $44.31 | 2023 | Uptravi, Opsumit |
| Biocon Biologics INC | $41.32 | 2024 | Hulio |
| Mallinckrodt Enterprises LLC | $38.31 | 2019 | |
| Hikma Pharmaceuticals USA | $38.18 | 2021-2022 | |
| Kiniksa Pharmaceuticals, Ltd. | $37.17 | 2023 | Arcalyst |
| Invivyd INC | $33.15 | 2025 | Pemgarda |
| Kiniksa Pharmaceuticals International, Plc | $29.22 | 2024 | Arcalyst |
| Fidia Pharma USA INC. | $27.18 | 2024 | Triluron |
| Tonix Medicines, INC. | $20.56 | 2025 | Tonmya |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sahdev Saharan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.